PTPN11 and dilated cardiomyopathy: Indeed, independent investigations demonstrated that both Q79R SHP2 gain of function and lack of SHP2-induced hyperactivation of ERK1/2 and RhoA signaling, leading to impaired heart function and dilated cardiomyopathy [44, 45].